Lyell Immunopharma (LYEL) AI Stock Analysis

• Market Cap: $507.63M
• Dividend Yield: N/A
• Average Volume (3M): 101.82K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.55
• Revenue Growth: -34.92%
• EPS Growth: -43.26%
• Country: US
• Employees: 300
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -7.18
• Shares Outstanding: 23,307,142
• 10 Day Avg. Volume: 80,410
• 30 Day Avg. Volume: 101,816
• PEG Ratio: >-0.01
• Price to Book (P/B): 2.12
• Price to Sales (P/S): 14614.51
• P/FCF Ratio: -3.49
• Enterprise Value/Market Cap: 1.02
• Enterprise Value/Revenue: 14.33K
• Enterprise Value/Gross Profit: -218.43
• Enterprise Value/Ebitda: -2.68
• 1Y Price Target: $39.50
• Price Target Upside: 81.36% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -9.33
• Revenue Forecast (FY): $18.00K

• Rating: 47 Neutral
• Price Target: $19.00 ▼(-12.76% Downside)
• Action: Reiterated Date: 03/13/26
• Date: Action: Reiterated 03/13/26

The score is held down primarily by very weak financial performance (minimal revenue, large losses, and substantial ongoing cash burn), despite a comparatively modest-debt balance sheet. Technicals are moderately supportive with price above key moving averages and neutral momentum, but valuation remains challenged because profitability is negative and there is no dividend support.

Positive Factors

Proprietary cell therapy platform

Lyell’s core scientific focus targets T cell exhaustion and durability in solid tumors, a structural unmet need in cell therapy. Proprietary approaches to T‑cell function create a potential durable competitive advantage and increase odds of differentiated clinical outcomes and partner interest over time.

Negative Factors

Minimal and collapsing revenue base

Revenue has effectively vanished, eliminating internal revenue sources to fund operations. For a biotech without commercial products, this intensifies reliance on external financing and partnerships and leaves no near-term route to margins or cash generation absent successful product commercialization.

Lyell Immunopharma Business Overview & Revenue Model

Company Description

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology ...

Read more

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology ...

How the Company Makes Money

null...

Lyell Immunopharma Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	36.00K	61.00K	130.00K	84.68M	10.65M
Gross Profit	-11.50M	61.00K	130.00K	84.68M	10.65M
EBITDA	-192.24M	-200.64M	-226.76M	-169.04M	-201.15M
Net Income	-274.45M	-342.99M	-234.63M	-183.12M	-250.22M
Balance Sheet
Total Assets	340.05M	490.86M	750.03M	937.56M	1.13B
Cash, Cash Equivalents and Short-Term Investments	247.22M	370.53M	546.22M	640.15M	614.79M
Total Debt	41.92M	58.97M	63.17M	67.70M	67.82M
Total Liabilities	91.85M	108.03M	95.08M	104.31M	197.62M
Stockholders Equity	248.20M	382.82M	654.95M	833.25M	929.79M
Cash Flow
Free Cash Flow	-150.80M	-162.86M	-166.38M	-193.83M	-191.75M
Operating Cash Flow	-150.02M	-162.39M	-163.69M	-169.56M	-126.25M
Investing Cash Flow	54.10M	122.42M	184.05M	-11.54M	-121.57M
Financing Cash Flow	50.41M	1.33M	1.74M	10.63M	401.24M

Lyell Immunopharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 21.78
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LYEL, the sentiment is Positive. The current price of 21.78 is above the 20-day moving average (MA) of 21.11, below the 50-day MA of 22.76, and above the 200-day MA of 18.69, indicating a neutral trend. The MACD of -0.59 indicates Negative momentum. The RSI at 51.41 is Neutral, neither overbought nor oversold. The STOCH value of 79.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LYEL.

Lyell Immunopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
REPL	53 Neutral	$644.07M	-3.16	-102.69%	―	―	-15.77%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RCKT	50 Neutral	$377.82M	-2.29	-65.76%	―	―	18.39%
LYEL	47 Neutral	$507.63M	-1.92	-90.52%	―	-34.92%	-43.26%
EDIT	44 Neutral	$268.17M	-1.14	-523.29%	―	-24.90%	7.19%
MREO	42 Neutral	$52.00M	-1.59	-83.02%	―	―	―